{
    "clinical_study": {
        "@rank": "102369", 
        "arm_group": [
            {
                "arm_group_label": "NAFT500 (pediatric)", 
                "arm_group_type": "Experimental", 
                "description": "Topical once a day for two weeks"
            }, 
            {
                "arm_group_label": "NAFT600 (pediatric)", 
                "arm_group_type": "Experimental", 
                "description": "Topical once a day for two weeks"
            }, 
            {
                "arm_group_label": "NAFT500 (adult)", 
                "arm_group_type": "Experimental", 
                "description": "Topical once a day for two weeks"
            }, 
            {
                "arm_group_label": "NAFT600 (adult)", 
                "arm_group_type": "Experimental", 
                "description": "Topical once a day for two weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to see how the body is affected when a study drug is applied to\n      both feet if the subject has athlete's foot or to both feet and the groin area if the\n      subject have both athlete's foot and jock itch. Safety of the drug and how well the drug\n      works will also be measured."
        }, 
        "brief_title": "Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Tinea Pedis", 
            "Tinea Cruris"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Tinea", 
                "Tinea Pedis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study population, diagnosis, and main criteria for inclusion:\n\n      Tinea pedis and Tinea cruris (NAFT-500):\n\n      Male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with\n      Tinea pedis and Tinea cruris infections confirmed by a positive KOH analysis from both the\n      feet and bikini area. Both cases (feet and bikini area) must be characterized by clinical\n      evidence of a Tinea pedis and Tinea cruris infection. Additional, approximately 4 PK\n      evaluable adult subjects with the same condition will serve as a control.\n\n      Tinea pedis (NAFT-600):\n\n      Male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with\n      Tinea pedis infection confirmed by a positive KOH analysis from both feet. Both feet must be\n      characterized by clinical evidence of a Tinea pedis infection. Additional, approximately 4\n      PK evaluable adult subjects with the same condition will serve as a control."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have Tinea pedis on both feet and Tinea cruris infections for NAFT-500,\n             both conditions must be characterized by clinical evidence of a Tinea infection.\n\n          -  Subjects must have Tinea pedis on both feet for NAFT-600, the condition must be\n             characterized by clinical evidence of a Tinea infection\n\n        Exclusion Criteria:\n\n          -  A known hypersensitivity to study medications or their components.\n\n          -  Any severe condition of Tinea pedis (incapacitating).\n\n          -  Any dermatological disease and or condition in the treatment or surrounding area that\n             may prevent application of the study product such as foot psoriasis, corns and /or\n             callus involving any web spaces, atopic or contact dermatitis.\n\n          -  Positive pregnancy test\n\n          -  Any history or current evidence(physical or laboratory) of anemia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712360", 
            "org_study_id": "MUS 90200/1023/0", 
            "secondary_id": "Tinea Pedis and Cruris"
        }, 
        "intervention": [
            {
                "arm_group_label": "NAFT500 (pediatric)", 
                "description": "Applied to both feet and groin area", 
                "intervention_name": "NAFT500 (pediatric)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NAFT500", 
                    "naftifine"
                ]
            }, 
            {
                "arm_group_label": "NAFT600 (pediatric)", 
                "description": "Applied to both feet only", 
                "intervention_name": "NAFT600 (pediatric)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NAFT600", 
                    "naftifine"
                ]
            }, 
            {
                "arm_group_label": "NAFT500 (adult)", 
                "description": "Applied to both feet and groin area", 
                "intervention_name": "NAFT500 (adult)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NAFT500", 
                    "naftifine"
                ]
            }, 
            {
                "arm_group_label": "NAFT600 (adult)", 
                "description": "Applied to both feet", 
                "intervention_name": "NAFT600 (adult)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NAFT600", 
                    "naftifine"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naftifine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tinea Pedis", 
            "Tinea Cruris", 
            "Athlete foot", 
            "Jock itch"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "Merz Investigative Site# 001272"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77845"
                    }, 
                    "name": "Merz Investigative Site #0001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santo Domingo", 
                        "country": "Dominican Republic"
                    }, 
                    "name": "Merz Investigative Site# 180001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Pedro Sula", 
                        "country": "Honduras"
                    }, 
                    "name": "Merz Investigative Site# 504001"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Dominican Republic", 
                "Honduras"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis", 
        "overall_official": {
            "affiliation": "Merz Pharmaceutical, LLC", 
            "last_name": "Stefan Plaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Variables will be derived from naftifine plasma concentration at day 1. Variables to be analyzed:\nPartial area under the plasma concentration-time curve (0-24 hours postdose) (AUC), calculated using the linear trapezoid rule.\nMaximum observed plasma concentration (Cmax); the highest plasma concentration in each subject after single dose.\nVariables will be derived from naftifine plasma concentration at day 14. Variables to be analyzed:\nArea under the plasma concentration-time curve (AUC) within one dosing interval at steady state .\nMaximum observed plasma concentration (Cmax); the highest plasma concentration in each subject at steady state", 
            "measure": "Naftifine hydrochloride pharmacokinetics variables, single and multiple dose", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\" Efficacy variables to be analyzed after 2 weeks of once daily application of both products ( NAFT-500 or NAFT-600 ) Efficacy variables to be analyzed\nComplete cure\nTreatment effectiveness\nMycological cure\nClinical success\nClinical cure\nSubject satisfaction", 
                "measure": "Efficacy variables", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Variables will be derived from naftifine plasma concentration at predetermined timepoints.\nTrough naftifine plasma concentration variables:\nTrough plasma concentrations\nTime (days) to maximal trough plasma concentration\nMaximum observed trough plasma concentration; the highest trough plasma concentration in each subject", 
                "measure": "Time of maximum naftifine plasma concentration after single dose and steady state multiple dose.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and day 14"
            }, 
            {
                "description": "Variables will be derived from naftifine urine concentration at predetermined timepoints day 1 and day 14. Variables to be analyzed:\nPartial amount of unchanged drug excreted into urine within the first 24 hours after single dose\nFraction of administrated drug excreted into urine (%)\nRenal clearance\nAfter multiple doses\nAmount of unchanged drug excreted into urine during a dosing interval at steady state\nFraction of administrated drug excreted into urine during a dosing interval at steady state\nRenal clearance", 
                "measure": "Naftifine hydrochloride pharmacokinetic variables in Urine, single dose and multiple dose", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and day 14"
            }
        ], 
        "source": "Merz Pharmaceuticals, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}